Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.